{
    "clinical_study": {
        "@rank": "149629", 
        "arm_group": [
            {
                "arm_group_label": "Losartan Tablets & QingReMoShen Granule", 
                "arm_group_type": "Experimental", 
                "description": "Losartan Tablets: 50mg, qd, po. QingReMoShen Granule: 12g, tid, po."
            }, 
            {
                "arm_group_label": "Losartan Tablets & Placebo Granule", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Losartan Tablets: 50mg, qd, po. Placebo Granule: 12g, tid, po."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the clinical safety and efficacy of QingReMoShen\n      Granule to treat idiopathic membranous nephropathy."
        }, 
        "brief_title": "Clinical Study of QingReMoShen Granule to Treat Idiopathic Membranous Nephropathy", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Idiopathic Membranous Nephropathy", 
        "condition_browse": {
            "mesh_term": [
                "Glomerulonephritis, Membranous", 
                "Kidney Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Women and men who had a clinic and biopsy-proven idiopathic membranous nephropathy;\n\n          -  6.0g\u226524 hour urinary protein\u22651.0g;\n\n          -  serum albumin concentration\u226526g/L;\n\n          -  Chronic Kidney Disease (CKD)\u22643 stage (eGFR\uff1e30ml/min/1.73m2 MDRD);\n\n          -  Willing to participate in the trial and signed an informed consent.\n\n        Exclusion Criteria:\n\n          -  Secondary membranous nephropathy;\n\n          -  Patients with one of the following circumstances- malignant tumors or malignancy, HIV\n             infection, a history of mental illness, any serious systemic infection, serious\n             gastrointestinal diseases, circulating hepatitis B surface antigens positive or\n             persistent abnormal serum transaminase, abnormal glucose metabolism or diabetes\n             mellitus;\n\n          -  Pregnant and lactating women;\n\n          -  Undergoing other clinical trials."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "72", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01845688", 
            "org_study_id": "ShanghaiSTCSM-2011", 
            "secondary_id": "11DZ1972703"
        }, 
        "intervention": [
            {
                "arm_group_label": "Losartan Tablets & QingReMoShen Granule", 
                "intervention_name": "Losartan Tablets & QingReMoShen Granule", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Losartan Tablets & Placebo Granule", 
                "intervention_name": "Losartan Tablets & Placebo Granule", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Losartan"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Idiopathic Membranous Nephropathy", 
            "Traditional Chinese Medicine", 
            "Randomized Control Trial"
        ], 
        "lastchanged_date": "May 18, 2013", 
        "location": {
            "contact": {
                "email": "happytlynn@163.com", 
                "last_name": "Lin Wang, PHD,MD", 
                "phone": "86-13816583673"
            }, 
            "facility": {
                "address": {
                    "city": "Shanghai", 
                    "country": "China", 
                    "state": "Shanghai", 
                    "zip": "200032"
                }, 
                "name": "Shanghai University of Traditional Chinese Medicine"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Efficacy and Safety Evaluation of QingReMoShen Granule in the Treatment of Idiopathic Membranous Nephropathy : A Randomized Double-Blind Controlled Clinical Study", 
        "other_outcome": {
            "description": "Detecting by flow cytometry method", 
            "measure": "T-cell classification", 
            "safety_issue": "No", 
            "time_frame": "At the 24thweek"
        }, 
        "overall_contact": {
            "email": "happytlynn@163.com", 
            "last_name": "Lin Wang, PHD,MD", 
            "phone": "86-13816583673"
        }, 
        "overall_official": {
            "affiliation": "Shanghai University of Traditional Chinese Medicine", 
            "last_name": "Lin Wang, PHD,MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "24-hour urine protein", 
            "safety_issue": "No", 
            "time_frame": "At the 24thweek"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01845688"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Shanghai University of Traditional Chinese Medicine", 
            "investigator_full_name": "wanglin", 
            "investigator_title": "Deputy director of Physicians", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "serum albumin concentration", 
                "safety_issue": "No", 
                "time_frame": "At the 24thweek"
            }, 
            {
                "measure": "eGFR", 
                "safety_issue": "Yes", 
                "time_frame": "At the 24thweek"
            }, 
            {
                "measure": "Alanine transaminase", 
                "safety_issue": "Yes", 
                "time_frame": "At the 24thweek"
            }
        ], 
        "source": "Shanghai University of Traditional Chinese Medicine", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "wanglin", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}